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Abstract 
Acetylshikonin, teracrylshikonin, /3,/3-dimethylacrylshikonin a dshikonin, isolated from Arnebia euchroma, inhibited collagen (10 
/xg/ml)-induced aggregation of washed rabbit platelets in a concentration-dependent manner with IC5o values of 2.1 + 0.2, 2.8 + 0.3, 
4.2 ___ 0.5 and 10.7 + 0.7 p,M, respectively. Acetylshikonin also inhibited the aggregation and ATP release of washed rabbit platelets 
induced by arachidonic acid (AA, 100 /~M), U46619 (1 /zM), platelet-activating factor (PAF, 3.6 nM) and thrombin (0.1 U/ml) in a 
concentration-dependent manner. The IC5o values of acetylshikonin on the inhibition of these four agonists-induced platelet aggregation 
were 3.1 + 0.4, 2.2 + 0.2, 8.0 + 0.6 and 12.7 + 1.0 /zM, respectively. The thromboxane B 2 formation caused by collagen, PAF and 
thrombin was inhibited by acetylshikonin, while formations of thromboxane B 2 and prostaglandin D 2 caused by AA were not inhibited. 
Acetylshikonin did not inhibit cyclooxygenase activity since it did not attenuate prostaglandin E 2 formation after incubation of sheep 
vesicular gland microsomes with AA. Acetylshikonin suppressed both the rise of intracellular Ca 2÷ concentration and the generation of 
[3H]inositol monophosphate caused by these five aggregation i ducers. Piatelet cyclic AMP level was unaffected by acetylshikonin. 
These data indicate that acetylshikonin hibits platelet activation by suppression of phosphoinositide breakdown. 
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1. Introduction 
Platelets are activated by a wide variety of stimuli in 
vivo, including diseased arteries [1]. The morphologic 
evidence that arterial thrombi are composed predominantly 
of platelet aggregates (white thrombi) [2] has led many 
investigators to postulate that platelet aggregation is the 
major pathogenetic mechanism in arterial thrombosis. 
Many lines of evidence also suggest that platelet-vessel 
wall interactions ignificantly contribute to the pathogene- 
sis of atherosclerosis, myocardial infarction and unstable 
angina pectoris [3-5]. Mural thrombus formation can re- 
strict the flow of blood to vital tissues or organs leading to 
peripheral, cerebral or coronary ischemia. The developing 
thrombus may embolize with potentially lethal conse- 
quences. Activation of platelets may not only lead to acute 
vascular complications uch as thrombosis but also, per- 
haps due to the release of growth factors, to long-term 
effects such as smooth muscle proliferation, one of the 
hallmarks of atherosclerosis [3,5]. Therefore, inhibition of 
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platelet function may be a promising approach for the 
prevention and treatment of diseases in which a pathophys- 
iological participation of activated platelets appears likely. 
Chinese herbs have been used traditionally as important 
remedies in Oriental medicine. Arnebia euchroma is one 
of the so-called 'vasoactive-antithrombotic'  herbal 
medicines in China. There are some reports that it had 
anti-inflammatory, antibacterial and antitumor actions [6]. 
Acety lsh ikon in ,  teracry lsh ikonin,  /3, /3-dimethyl-  
acrylshikonin and shikonin are four active principles iso- 
lated from Arnebia euchroma. Recently, we found that 
these four shikonin derivatives all possessed antiplatelet 
activity. In this paper, we have tried to elucidate the 
mechanism(s) of their inhibitory activity on platelet aggre- 
gation. 
2. Materials and Methods 
2.1. Materials 
Acetylshikonin, teracrylshikonin, /3,/3-dimethylshikonin 
and shikonin (Fig. 1) were isolated from the plant, Arnebia 
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Fig. 1. Chemical structures of /3,/3-dimethylacrylshikonin (I), teracryl- 
shikonin (II), shikonin (III) and acetylshikonin (IV). 
euchroma (Royle) Johnst (Boraginaceae), asdescribed pre- 
viously [7]. Collagen (type I, bovine Achilles tendon), 
from Sigma Chemicals, was homogenized in 25 mM acetic 
acid and stored (1 mg/ml) at -70°C. Bovine thrombin 
obtained from Parke Davis was dissolved in glycerol (50%, 
v /v)  for a stock solution of 100 NIH units/ml. Platelet- 
activating factor (PAF; 1-0-alkyl-2-acetyl-sn-glycerol-3- 
phosphocholine) purchased from Sigma Chemical was dis- 
solved in chloroform and diluted into 0.1% BSA/saline 
solution immediately before use. Bovine serum albumin 
(BSA), arachidonic acid (AA), U46619 (9,11-dideoxy- 
9c~,llc~-methanoepoxy PGFz~), fura-2/AM, phenyl- 
methyl sulfonyl fluoride (PMSF), indomethacin, EDTA 
(ethylenediaminetetraacetic acid, disodium salt), EGTA 
(ethyleneglycol-bis-(/3-aminoethyl t er) N,N,N',N'-tetra- 
acetic acid), luciferase-luciferin, trichloroacetic a id (TCA), 
Dowex-1 (100-200 mesh: x8, C1-) resin, imidazole, leu- 
petin, acrylamide, Tris-HC1 and myo-inositol were pur- 
chased from Sigma Chemicals. Phorbol 12,13-dibutyrate 
(PDBu), staurosporine and cyclooxygenase activity assay 
kit were obtained from Biomol Research Laboratory. Myo- 
[2-3H]inositol (10-20 Ci/mmol), [20-3H(n)]PDBu (10-20 
Ci/mmol), [T-32p]ATP (triethylammonium salt, 3000 
Ci/mmol) and prostaglandin E 2 radioimmunoassay (RIA) 
and PKC enzyme assay kits were purchased from Amer- 
sham. Thromboxane B z, prostaglandin D 2 and cyclic AMP 
enzyme immunoassay kits (EIA) were purchased from 
Cayman Chemicals. 
2.2. Methods 
Preparation of platelets 
Platelet-rich plasma (PRP) was obtained from blood 
collected from rabbit marginal vein, anticoagulated with 
sodium citrate (3.8%, 9:1 v /v)  and centrifuged for 10 min 
at 90 X g and room temperature. Platelet suspension was 
prepared from EDTA-anticoagulated PRP according to 
washing procedures described previously [8]. Platelets were 
counted by Hemalaser 2 (Sebia, France) and adjusted to a 
concentration f 3 × 108 platelets/ml. Platelet pellets were 
finally suspended in Tyrode's buffer (136.8 mM NaC1, 2.8 
mM KC1, 11.9 mM NaHCO 3, 2.1 mM MgC12, 0.33 mM 
NaH2PO 4, 1 mM CaCI 2, 11.2 mM glucose, pH 7.4) 
containing 0.35% BSA. 
Platelet aggregation and ATP release reaction 
Aggregation was measured by turbidimetry as described 
by O'Brien [9]. ATP released from platelets was detected 
by the bioluminescence method of DeLuca and McElory 
[10]. Both aggregation and ATP release were simultane- 
ously measured in a Lumi-aggregometer (Model 1020B, 
Payton, Canada) connected to two dual-channel recorders. 
Platelet preparations were stirred at 900 rpm. When 
dimethylsulfoxide (DMSO) was used as solvent, its final 
concentration was fixed at 0.5% (v/v)  to eliminate the 
effect of the solvent. 
Thromboxane B 2 and prostaglandin D2 assay 
After 6 min of platelet incubation with the inducer, 
EDTA (2 raM) and indomethacin (50 /xM) were added to 
halt thromboxane and prostaglandin D 2 formation. After 
centrifugation i  an Eppendorf microcentrifuge (Model 
5415 C) for 2 min, thromboxane B 2 and prostaglandin D 2 
in the supernatant were assayed by EIA. 
Assay of cyclooxygenase activity 
The effect of acetylshikonin on cyclooxygenase activity 
was determined using a cyclooxygenase activity assay kit 
(Biomol). In brief, sheep vesicular gland microsomes (0.2 
mg/ml; 100 /xl) were incubated with DMSO (2 /xl), 
indomethacin (0.01 mg/2 /zl) or various concentrations of 
acetylshikonin (2 /xl) at 4°C for 3 min. Reaction cofactor 
(epinephrine, tryptophan, hydroquinone and GSH; 10 /xl) 
was then added and incubated at 25°C for 3 min with 
shaking. After that, arachidonic acid (2 /xg/2 /xl) was 
added and incubated for another 3 min. FeCI 2 (25 mM, 10 
/xl) was then added to halt the reaction. Reaction mixture 
was allowed to stand at room temperature for 15 min. 
After centrifugation at 3000 × g and 4°C for 10 min, 
prostaglandin E 2 in the supernatant was assayed by RIA. 
The cyclooxygenase activity was reflected by the prosta- 
glandin E 2 production. 
Measurement of intracellular calcium in platelets 
The method of Pollock and Rink was followed [11]. 
Platelets (3 X 108/ml) were incubated with fura-2/AM (5 
/xM) at 37°C for 40 min, centrifuged at 500 X g and the 
resultant pellet was washed with EDTA (1 mM) containing 
Tyrode solution. After centrifugation, platelets were resus- 
pended in the Tyrode solution containing 1 mM Ca 2+. 
Fluorescence (ex. 339 nm, Em. 500 nm) was measured 
with a Hitachi Fluorescence Spectrophotometer (Model 
F4000). At the end of the experiment the cells were treated 
with 0.1% Triton X-100 followed by the addition of I0 
mM EGTA to obtain the maximal and minimal fluores- 
cence, respectively. [Ca 2+ ]i was calculated as described 
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for fura-2 using Ca2+-dye dissociation constant of 224 nM 
[12]. 
Labelling of membrane phospholipids and measurement of 
the production of [ 3H]inositol phosphate 
The method employed was modified from those of 
Huang and Detwiler [13] and Neylon and Summers [14]. 
EDTA-PRP was centrifuged at 500 × g for 10 min. Platelet 
pellets were then suspended in 1 ml of Ca2÷-free and 
BSA-free Tyrode's solution containing of myo-[2-3H]in - 
ositol (75 /zCi/ml) and E1-)TA (1 mM). After incubation 
for 2 h at 37°C, the platelets were collected by centrifuga- 
tion (500 × g, 4 min) and suspended in Tyrode's olution. 
Phosphoinositide breakdown was measured by addition of 
aggregation inducers to platelet suspension (1 ml) in a 
3.5-ml cuvette with a stining bar driven at 1200 rpm. 
Incubation was continued for 6 min at 37°C. An equal 
volume of 10% (w/v)  trichloroacetic a id (TCA) was then 
added to stop the reaction. After centrifugation at 1000 × g 
for 10 min, 1 ml of supematant was aspirated and TCA 
removed by washing with diethyl ether. The aqueous phase 
containing inositol phosphates was adjusted to pH 7-8, 
diluted to 4 ml with distilled water, and applied to a 
Dowex-1 ion-exchange column for separation of inositol 
phosphates as described by Neylon and Summers [14]. All 
experiments were carried out in the presence of 5 mM 
LiC1 to inhibit inositol monophosphate phosphatase. Be- 
cause concentrations of inositol bisphosphate and inositol 
trisphosphate were very low, we measured inositol 
monophosphate as an index of the total inositolphosphate 
formation. 
Cyclic AMP assay 
The method of Karniguian et al. [15] was followed. 
Platelet suspension (109 platelets/ml) was warmed at 
37°C for 1 min, PGE 1 or acetylshikonin was then added 
with incubation for 45 s. The reaction was stopped by 
adding 10 mM EDTA followed immediately by boiling for 
5 min. Upon cooling to 4°C, precipitated protein was 
sedimented by centrifugation i  an Eppendorf microcentri- 
fuge (Model 5415 C). The supernatant was used to assay 
for cyclic AMP content by EIA. 
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Fig. 2. A: Concentration-response curves of shikonin derivatives on the 
aggregation of washed rabbit platelets induced by collagen. Platelets were 
preincubated with DMSO (0.5%, control) or various concentrations of
/3,/3-dimethylacrylshikonin (O), teracrylshikonin (O), acetylshikonin ( zx ) 
or shikonin (• )  at 37°C for 3 min, then collagen (10/xg/ml) was added 
to trigger the aggregation. Percentages of aggregation are presented as 
means + S.E.M. (n = 4). B: Concentration-dependent inhibition of acetyl- 
shikonin on platelet aggregation i duced by AA (100 /xM, O), collagen 
(10 /~g/ml, zx), U46619 (1 p,M, O), PAF (3.6 nM, • )  and thrombin 
(0.1 U/ml,  D). Washed rabbit platelets were preincubated with DMSO 
(0.5%, control) or various concentrations of acetylshikonin at37°C for 3 
min, then the inducer was added to trigger the aggregation. Values are 
presented as means ___ S.E.M. (n = 6). 
dependent manner with IC50 values of 2.1 ___ 0.2, 2.8 ___ 0.3, 
4.2 + 0.5 and 10.7 ___ 0.7/xM, respectively (Fig. 2A). The 
properties and mechanism(s) of action of acetylshikonin 
were then studied in the following experiments. 
3.2. Effects of acetylshikonin on the aggregation and ATP 
release reaction of washed rabbit platelets 
3. Results 
3.1. Comparison of acetylshikonin and its analogues on 
collagen-induced aggregation of washed rabbit platelets 
The antiplatelet activities of acetylshikonin and its ana- 
logues were compared in collagen-induced aggregation of 
washed rabbit platelets. In washed rabbit platelets, colla- 
gen (10 Izg/ml) caused 89.0 + 0.3% aggregation (  = 4). 
Acetylshikonin, teracrylshikonin, /3,f l-dimethyl- 
acrylshikonin and shikonin all inhibited collagen-induced 
aggregation of washed rabbit platelets in a concentration- 
As well as collagen (10/zg/ml), arachidonic acid (AA, 
100 tzM), U46619 (1 /zM), PAF (3.6 nM) and thrombin 
(0.1 U/ml) all caused about 90% aggregation i washed 
rabbit platelets. Acetylshikonin inhibited AA-, U46619-, 
PAF- and thrombin-induced aggregation of washed rabbit 
platelets in a concentration-dependent manner with IC50 
values of 3.1 __+ 0.4, 2.2 ___ 0.2, 8.0 ___ 0.6 and 12.7 + 1.0 
/xM, respectively (Fig. 2B). In addition to the inhibition of 
platelet aggregation, acetylshikonin also inhibited colla- 
gen-, AA-, U46619-, PAF- and thrombin-induced ATP 
release in a concentration-dependent manner. Inhibition of 
ATP release was parallel to the inhibition of platelet 
aggregation (data not shown). 
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Table 1 
Effects of acetylshikonin on the thromboxane B z formation of washed rabbit platelets caused by AA, collagen, U46619, PAF and thrombin 
Thromboxane B 2 (ng /3  × 108 platelets) 
AA Collagen U46619 PAF Thrombin 
Control 
Acetylshikonin 1 /zM 
3 p.M 
6 /xM 
10/xM 
20 p,M 
50 /xM 
456 4- 62 184 4- 20 3.2 +__ 1.5 
161 + 36 
309 4- 45 73+ 17 *** 
430 4- 113 15 4- 1 * * * 3.2 4- 1.0 
29.0 + 6.8 31.0 _+ 10.0 
12.6 4- 4.1 * 22.0 + 12.0 
8.4 4- 1.4 * 9.0 4- 3.0 * 
8.0 4- 2.0 * 
5.0 _+ 2.0 * * 
DMSO (0.5%, control) or various concentrations of acetylshikonin were preincubated with platelets at 37°C for 3 min, then AA (100 /xM), collagen (10 
/xg/ml) ,  U46619 (1 /xM), PAF (3.6 nM) or thrombin (0.1 U /ml )  was added for another 6 min. The thromboxane B 2 level of resting platelets was 
1.5 4- 0.3 ng /3  × 108 platelets. Values are presented as means +__ S.E.M. (n = 6). * P < 0.05; * * P < 0.01; ~ * * P < 0.001 as compared with the 
respective control. 
3.3. Effects of acetylshikonin on platelet hromboxane B 2 
and prostaglandin D2 formation 
The thromboxane B 2 level of resting platelets was 
1.5 ± 0.3 ng/3 × 108 platelets. U46619 (1 /xM) failed to 
raise the thromboxane B 2 level significantly, whereas AA 
(100 /xM), collagen (10 /xg/ml), PAF (3.6 nM) and 
thrombin (0.1 U/ml) caused markedly thromboxane B 2 
formation in washed rabbit platelets (Table 1). Acetyl- 
shikonin inhibited collagen-, PAF- and thrombin-induced 
thromboxane B 2 formation in a concentration-dependent 
manner, without affecting that formation caused by AA 
(Table 1). The prostaglandin D 2 level of resting platelets 
was low (0.12_+0.07 ng/3 X 108 platelets). However, 
prostaglandin D 2 formed in the presence of AA. This 
prostaglandin D 2 formation was inhibited by indo- 
methacin, but enhanced markedly by imidazole. Acetyl- 
shikonin slightly increased this AA-induced prostaglandin 
D 2 formation (Table 2). 
3.4. Effect of acetylshikonin on the cyclooxygenase activity 
The cyclooxygenase activity was reflected by the 
prostaglandin E 2 production. After incubation of sheep 
Table 2 
Effects of acetylshikonin, indomethacin and imidazole on the prosta- 
glandin D 2 formation of washed rabbit platelets caused by AA 
Prostaglandin D 2 
(ng /3  X 108 platelets) 
Resting 0.12 + 0.07 
DMSO + AA 3.40 + 0.63 
Acetylshikonin + AA 7.60 + 1.28 * * 
Indomethacin + AA 0.30 + 0.03 * * * 
Imidazole + AA 93.4 4- 10.3 * * * 
DMSO (0.5%), acetylshikonin (6 /xM), indomethacin (2 /xM) or imida- 
zole (1 mM) was preincubated with platelets at 37°(2 for 3 min, then AA 
(100 /zM) was added for another 6 min. Values are presented as 
means+ S.E.M. (n = 6). * * P < 0.01; * * * P < 0.001 as compared with 
AA. 
vesicular gland microsomes with AA at 25°C for 3 min, 
the prostaglandin E 2 formation was 40.1 _+ 11.0 ng/ml. 
Indomethacin markedly inhibited while acetylshikonin did 
not affect his prostaglandin E 2 formation (Fig. 3). 
3.5. Effect of acetylshikonin on phosphoinositide break- 
down 
In [3H]inositol-labeled washed rabbit platelets, U46619 
(1 /zM), PAF (3.6 nM) and thrombin (0.1 U/ml) in- 
creased the [3H]inositol monophosphate formation 3.0_ 
0.5-, 2.1 ___ 0.2- and 7.6_ 1.4-folds, respectively, in the 
presence of indomethacin (2 /zM). AA (100 /xM) and 
collagen (10/xg/ml), in the absence of indomethacin, also 
increased the [3H]inositol monophosphate formation 2.1 ___ 
0.2- and 2.5_ 0.4-folds, respectively. Acetylshikonin (6 
or 20 /zM) markedly inhibited the [3H]inositol monophos- 
phate formation caused by the five inducers (Fig. 4). 
6O 
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Fig. 3. Effects of acetylshikonin and indomethacin on the cyclooxygenase 
activity. 60 sheep vesicular gland microsomes were incubated with 
DMSO (0.5%, []), indomethacin (0.01 mg, • ) or various concentrations 
of acetylshikonin (0.5 /zM, left-hatched; 1 /.~M, right-hatched; 3 /xM, 
cross-hatched; 6 p,M, fine cross-hatched) at 4°C for 3 min, then the 
cofactors (epinephrine, tryptophan, hydroquinone and GSH) were added 
and incubated at 25°C for another 3 min. After AA (2 /xg) was added to 
trigger the prostaglandin E 2 production at 25°C for 3 min, the reaction 
was stopped by FeC12 (25 raM, l0/1,1). The cyclooxygenase activity was 
reflected by prostaglandin E 2 production which are presented as means + 
S.E.M. (n = 4). * * P < 0.01 as compared with the control. 
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Fig. 4. Inhibitory effects of acetylshikonin on the formation of inositol 
monophosphate caused by some aggregation i ducers in washed rabbit 
platelets. [3H]Inositol-labeled platelets were incubated with DMSO (0.5%, 
E3) or acetylshikonin (6 /zM, left-hatched; 20 /xM, cross-hatched) at
37°C for 3 min, then AA (100 /zM), collagen (10 /xg/ml), U46619 (1 
/xM), PAF (3.6 nM) or thrombin (0.1 U/ml )  was added and incubated 
for another 6 min. Indomethacin (2 /xM) was presented in the medium 
except hose challenged by AA and collagen. Increase in inositol phos- 
phate (IP) are presented as means J-S.E.M. (n = 4). * P < 0.05, * * P < 
0.01, * * * P < 0.001 as compared with the respective control. 
3.6. Effect of acetylshikonin o  the intracellular calcium of 
platelets 
In fura-2-1oaded platelets, U46619, PAF and thrombin 
caused an increase of [Ca"+] i in the presence of indo- 
methacin (2 /xM). AA and collagen also increased the 
[Ca2+]i in the absence of indomethacin. The rise was only 
short-lived, and apparent l[Ca2+]i declined towards the 
resting level within a few minutes. This was due to the 
aggregates interfering with the fluorescence signal and 
constitutes a limitation of the technique. As shown in Fig. 
5, the rises of [Ca z+ ]i caused by AA, collagen and U46619, 
but not PAF and thrombin, were inhibited by low concen- 
tration of acetylshikonin (6 /~M). However, those caused 
by PAF and thrombin were almost completely inhibited by 
higher concentration of acetylshikonin (20 /zM, data not 
shown). 
3. 7. Effect of acetylshikonin on the cyclic AMP level of 
platelets 
The level of cyclic AMP in unstimulated platelets was 
3.6 -t- 0.5 pmol/109 platelets (n = 6). Prostaglandin E 1 of 
1 and 10/zM increased the cyclic AMP level to 61.3 + 14.4 
and 106.0 + 11.2 pmol/109 platelets (n = 6), respec- 
tively. Acetylshikonin (3-50 /~M) had no significant ef- 
fect on platelet cyclic AMP level (4.3 ___ 0.7 pmol/109 
platelets for 50 ~M acetylshikonin,  = 6). 
4. Discussion 
Acetylshikonin inhibited AA-, U46619-, collagen-, 
PAF- and thrombin-induced platelet aggregation and ATP 
release in a concentration-dependent manner. Acetyl- 
shikonin also inhibited collagen-, PAF- and thrombin-in- 
duced thromboxane B 2 formation without affecting that 
cg 
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Fig. 5. Effects of acetylshikonin on the increase of intracellular calcium concentration caused by some aggregation i ducers in fura-2-1oaded platelets. 
Fura-2-1oaded washed rabbit platelets were preincubated with DMSO (0.5%) or acetylshikonin at 37°C for 3 min, then AA (100 /xM), collagen (10 
/~g/ml), U46619 (1 /~M), PAF (3.6 nM) or thrombin (0.1U/ml) was added. Indomethacin (2 /xM) was presented in the medium except hose challenged 
by AA and collagen. 
334 F.-N. Ko et aL / Biochimica et Biophysica Acta 1268 (1995) 329-334 
formation caused by AA. Phosphoinositide breakdown is 
an important pathway in signal transduction of agonist-in- 
duced platelet activation. Indeed, the primary biological 
signal caused by many aggregation i ducers is clearly the 
increase of phosphatidylinositol breakdown [ 16,17]. This 
process generates two active products, diacylglycerol and 
inositol tfisphosphate. Diacylglycerol activates PKC, lead- 
ing to protein phosphorylation a d release reaction. Inosi- 
tol trisphosphate riggers calcium mobilization from intra- 
cellular compartments [18]. The rise of [Ca2+]i is very 
important for both the release reaction and the activation 
of phospholipase A 2, which is a rate-limiting enzyme for 
the generation of arachidonic acid. Acetylshikonin inhib- 
ited AA-, U46619-, collagen-, PAF- and thrombin-induced 
inositol phosphate formation and the rise of [Ca 2+ ]i' Thus, 
it may suppress these agonist-induced platelet aggregation, 
release reaction, thromboxane formation and rise of [Ca 2 + ]i 
by inhibition of agonist-induced phosphoinositide break- 
down. 
Elevation of cyclic AMP level, either by stimulation of 
adenylate cyclase or by inhibition of cyclic AMP-depen- 
dent phosphodiesterase, i  one of the most potent mecha- 
nisms of inhibition of platelet functions. Elevated cyclic 
AMP inhibits most platelet responses, including aggrega- 
tion, ATP release, phosphoinositide breakdown and rise of 
[ Ca2+ ]i [19]. Cyclic AMP can stimulate uptake of calcium 
into the dense tubular system and extrusion of calcium 
from the cell. In our experimental data, acetylshikonin did 
not elevate the cyclic AMP content of platelets. This 
indicates that the antiplatelet ffect of acetylshikonin s not 
mediated by elevation of platelet cyclic AMP levels. It also 
implies that the inhibition of platelet phosphoinositide 
breakdown and an intracellular calcium concentration of 
acetylshikonin s not caused by elevation of platelet cyclic 
AMP levels. 
Thromboxane A 2 is an important mediator of release 
reaction and aggregation of platelets. The aggregation and 
ATP release of platelets induced by AA are due to throm- 
boxane A 2 formation [20]. Early studies also suggested 
that ADP released from platelets timulated by aggregation 
inducers was responsible for further recruitment of the 
remaining ones, and thus for the formation of the aggre- 
gates. Both AA-induced thromboxane B 2 and prosta- 
glandin D z formation were not inhibited by acetylshikonin. 
Acetylshikonin also did not inhibit cyclooxygenase activity 
reflected by PGE 2 production after incubation of sheep 
vesicular gland microsomes with AA. Thus, acetylshikonin 
is not an inhibitor of platelet cyclooxygenase. The an- 
tiplatelet action of acetylshikonin may be not due to direct 
inhibition of thromboxane A 2 formation. 
The reason(s) why AA-induced PGD 2 formation was 
increased by acetylshikonin was unknown. However, the 
prostaglandin D 2 formation caused by acetylshikonin was 
very slight when compared with the formation caused by 
imidazole (Table 2). Furthermore, platelet cyclic AMP 
level was not elevated by acetylshikonin. Thus, this slight 
increase of PGD 2 formation may not contribute to the 
antiplatelet action of acetylshikonin. 
In conclusion, acetylshikonin hibits platelet activation 
by suppression of phosphoinositide breakdown. 
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